NEW YORK (GenomeWeb) – Avalon GloboCare said today that it has entered a strategic partnership with Da An Gene to "further optimize" Avalon's exosome technology, clinical development, and product commercialization.
Freehold, New Jersey-based Avalon said that as part of the collaboration, it will unite resources with Da An Gene to accelerate exosome-based in vitro diagnostic product development and commercialization. Da An Gene has intellectual property rights covering its proprietary core technology platform of fluorescent-quantitative PCR diagnostic reagents, Avalon said.
Avalon noted that Da An Gene — part of Sun Yat-sen University School of Medicine in Guangzhou, China — has agreed to prioritize the use and purchase of technologies and products of Avalon and of its subsidiary GenExosome Technologies. Avalon said that the partnership will promote and foster biomedical innovation and clinical advances in molecular pathology and regenerative medicine and take advantage of translational research at Sun Yat-sen University School of Medicine and affiliated hospitals.
Additional terms of the agreement were not disclosed.
David Jin, president and CEO of Avalon GloboCare, said in a statement that the strategic partnership with Da An Gene "will significantly accelerate our product development and commercialization in the fields of liquid biopsy and in vitro diagnostics." He noted that the partners would combine Da An's genomic sequencing and profiling platform with Avalon's proprietary exosome isolation system and clinical expertise in regenerative medicine.
Da An Gene participates in product research, development, commercialization, and application in the molecular diagnostics sector in China. Its research institutes in China include the Medical Biotechnology Research Center under the Ministry of Health; the Clinical Medical Molecular Diagnostic Engineering Laboratory of Guangdong Province; and Guangzhou Antibody Engineering Technology Research Center.